Categories: News

A taste of Chinese New Year in Guangdong: top picks from Consuls General in Guangzhou

GUANGZHOU, China, Feb. 20, 2026 /PRNewswire/ — A news report from South: It’s the Year of the Horse, and across Guangdong, the festive spirit of the Lunar New Year is in full swing—nowhere more so than at the dinner table.

- Advertisement -

Food has always been at the heart of the region’s New Year celebrations. For international friends staying in Guangdong over the holidays and wondering what to eat, we’ve got you covered.

- Advertisement -

Here’s the ultimate must-try list, handpicked by Consuls General in Guangzhou.

- Advertisement -

 

- Advertisement -

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/a-taste-of-chinese-new-year-in-guangdong-top-picks-from-consuls-general-in-guangzhou-302693317.html

- Advertisement -

Recent Posts

Nikon Metrology Receives Frost & Sullivan’s 2026 Global Product Leadership Recognition for Excellence in Laser Radar BIW Inspection

Recognized for advancing high-precision, in-line dimensional inspection and enabling data-driven manufacturing transformation in automotive productionSAN…

3 hours ago

GIGABYTE Opens COMPUTEX 2026 with ENTER INFINITY, Where AI, Gaming, and PC Innovation Unite

TAIPEI, June 2, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, today officially opened…

3 hours ago

GIGABYTE Unveils Award-Winning AI Gaming Laptops and Revolutionary GiMATE Updates at COMPUTEX 2026

TAIPEI, June 2, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, unveiled its AI…

3 hours ago

Stamus Networks Marks 10th Year Supporting NATO CCDCOE Cyber Defense Exercises

Company celebrates a decade of supporting the world's premier live-fire cyber defense exercises with expertise,…

4 hours ago

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogrens Disease at EULAR 2026

ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+…

6 hours ago

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed…

6 hours ago